Explorer les evidences

9 %Twenty-one (9%) of 230 patients in the efavirenz group experienced HIV-associated non-AIDS illnesses.

Côte d'IvoireHIV-associated non-AIDS illnessespublié 2021The Lancet. Infectious diseaseseurope_pmcdocument de 11 observationsDOI 10.1016/s1473-3099(20)30869-0

0 seroconversionsNo HIV and HBV seroconversion was observed after a 3-month follow-up among rape victims receiving antiretroviral chemoprophylaxis in Abidjan.

Côte d'Ivoirehépatite B · VIH/sidapublié 2015Medecine et maladies infectieuseseurope_pmcdocument de 3 observations

4,2 %Among the 943 inmates screened at the Correctional and Detention Facility of Abidjan, 40 (4.2%) had probable pulmonary TB.

Côte d'Ivoirepulmonary TBobservé 2015publié 2017PloS oneeurope_pmcdocument de 8 observations

17,9 %Cerebral toxoplasmosis accounted for 17.9% of AIDS-defining reasons for hospitalization.

Côte d'Ivoirecerebral toxoplasmosis · VIH/sidapublié 2013Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument de 16 observations

7,6 %The overall prevalence of severe cardiovascular abnormalities (SCA) in the study population was 7.6%.

Côte d'Ivoiresevere cardiovascular abnormalitiesobservé 2015publié 2021Southern African journal of infectious diseaseseurope_pmcdocument de 9 observationsDOI 10.4102/sajid.v36i1.187

8,6 %8.6% of patients interrupted antiretroviral chemoprophylaxis treatment.

Côte d'IvoireVIH/sidaobservé 2000-2007publié 2010Medecine et maladies infectieuseseurope_pmcdocument de 13 observations

21,49 %Malaria case prevalence in the LLIN plus Bti group was 21.49% (570/2652) pre-intervention.

Côte d'IvoirepaludismeHAL · Unilimdocument de 54 observations

0,5 per_100_person_weeksMalaria incidence rates remained below 0.5 cases per 100 person-weeks in the 5–18-year-old age group.

Côte d'IvoirepaludismeHAL · Unilimdocument de 122 observations

22,9 %Tuberculosis accounted for 22.9% of causes of death.

Côte d'Ivoiretuberculosepublié 2013Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument de 16 observations

Avascular osteonecrosis of the femoral head was diagnosed in all three patients, with unilateral involvement in two and bilateral involvement in one.

Côte d'Ivoireavascular osteonecrosis of the femoral headpublié 2009Antiviral therapyeurope_pmcdocument de 11 observations

86 cells/mm³CD4(+) T-cell nadirs were 86 cells/mm³, 99 cells/mm³, and 12 cells/mm³ for the three patients.

Côte d'IvoireVIH/sidapublié 2009Antiviral therapyeurope_pmcdocument de 11 observations

13 patients13 patients had been treated (21%).

Côte d'IvoireVIH/sidaobservé 1999–2006publié 2010Le Mali medicaleurope_pmcdocument de 17 observations

87 %At month 6, 87% of HIV-1-infected adults on zidovudine + lamivudine + efavirenz had undetectable viral load.

Côte d'IvoireVIH/sidaobservé month 6publié 2006Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument de 9 observationsDOI 10.1097/01.qai.0000219777.04927.50

75 %At month 24 after ART initiation, 75% of patients with detectable viral loads had resistant virus.

Côte d'IvoireVIH/sidapublié 2013Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument de 11 observations

186 per_mm3The median pre-antiretroviral treatment CD4 count was 186 per mm³.

Côte d'IvoireVIH/sidapublié 2013BMC infectious diseaseseurope_pmcdocument de 10 observationsDOI 10.1186/1471-2334-13-607

77,3 %Among 130 patients who reported a relevant clinical indicator, 92 (77.3%) experienced at least one missed opportunity for HIV testing.

Côte d'IvoireVIH/sidaobservé 2013–2014publié 2017PloS oneeurope_pmcdocument de 5 observations

4,7 %HIV prevalence was 4.7% in the referent group of 442 patients.

Côte d'IvoireVIH/sidapublié 2012PloS oneeurope_pmcdocument de 7 observationsDOI 10.1371/journal.pone.0048108

4 %The Senegal haplotype was detected in 4% of the samples.

Côte d'Ivoirehemoglobin disordersHAL · Unilimdocument de 23 observations

17,25 yearsDiscounted life expectancy was 17.25 years for adaptive viral load monitoring.

Côte d'IvoireVIH/sidapublié 2016Clinical infectious diseases : an official publication of the Infectious Diseases Society europe_pmcdocument de 5 observations

1,9 %HIV prevalence in the West and Central African region is 1.9%.

Côte d'IvoireVIH/sidapublié 2020International journal of infectious diseases : IJID : official publication of the Internateurope_pmcdocument de 3 observations

0 %Cumulative proportion of HBsAg seroclearance was 0% in patients with baseline pcG1896A mutation and 36.9% in those without, among antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.

Côte d'Ivoirehépatite Bpublié 2018Journal of viral hepatitiseurope_pmcdocument de 7 observationsDOI 10.1111/jvh.12914

78 %The median self-reported adherence rate to highly active antiretroviral therapy (HAART) was 78% among HIV-infected adults followed in field conditions in Abidjan.

Côte d'IvoireVIH/sidapublié 2007Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument de 2 observationsDOI 10.1097/qai.0b013e31805d8ad0

11 casesOf the 1023 HIV-1-infected adults randomized in the Temprano deferred-ART group, 11 (1.1%) were viremic controllers.

Côte d'IvoireVIH/sidapublié 2022AIDS (London, England)europe_pmcdocument de 3 observations

59,3 %Baseline pcG1896A mutation was identified in 51 (59.3%) of 86 antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.

Côte d'Ivoirehépatite Bpublié 2018Journal of viral hepatitiseurope_pmcdocument de 7 observationsDOI 10.1111/jvh.12914

6,8 %Among the 2056 patients, 6.8% were obese at baseline.

Côte d'Ivoireobésitépublié 2017PloS oneeurope_pmcdocument de 8 observations